US operations to be located in Southern California
GW Pharmaceuticals, a biopharmaceutical company developing medical products derived from cannabis, has appointed Julian Gangolli as President, North America and is also relocating its Chief Executive, Justin Gover, to the US.
Gangolli was previously President of the North American Pharmaceutical division of Allergan. He will join GW next month (June) and is expected to be appointed to the Board of Directors.
Prior to Allergan, Gangolli was Vice President, Sales and Marketing at Vivus; before this he held roles at Syntex Pharmaceuticals and Ortho-Cilag Pharmaceuticals in the UK.
Geoffrey Guy, GW’s Chairman, said: 'As Epidiolex nears its final stages of clinical development and as GW prepares for future US launch, the time is right to start building our in-house US commercial infrastructure.'
GW will locate its US operation in Southern California where both men will be based.
The company is also continuing to expand its UK manufacturing and R&D operations in preparation for future commercialisation as well as pipeline development. GW currently employs 325 people in the UK, up from 190 two years ago.